Member Info for BuenaVista

😂 "Keep the faith" is the most obvious red flag, waving and with flashing red lights, that anyone will ever see!

faith - noun: strong belief in the doctrines of a religion, based on spiritual conviction rather than proof.

Haha, the birthplace of Nelson!

It's a wonder Thomas can even it down.

Did anyone else feel the compulsion to click on the Avacta arrow?

The "unmissable" event and Avacta presentation? It was epoch-making! A first!! Truly!!!

Word on the street is that after a stunning presentation Victoria was literally mobbed, literally, with some of the lesser farmer men throwing their underwear at her, and none would let her leave the stage until she'd given three full encores. Some of the Novartis and AstraZeneca crews were seen sneaking off however during the encores. Rumour has it they were buying Avacta shares...

Harrogate wrote "I must have missed it. Can you remind me what the significant rise was?"

It was in quotes

Actually the share price rose 'signficantly' yesterday because it was the 4th of the month and it was a Thursday. It can be statistically proven that the share price shoots up when the 4th of the month falls on a Thursday.

Use an ad blocker. LSE occasionally throws up a 'You're using an ad blocker' screen that disables the site but there's a way round that.

I wouldn't pay for LSE unless it were a lot better designed and maintained. I accept that I'm the product.

@djframboise, it was meant as a joke. The 'England Expects' post contained a direct mention of Nelson.

You've probably upset a Frenchie, maybe djframboise.

OK, thank you.

I've been wondering why an essentially American company was set up in the UK back in 2013 and has only been listed on the London Stock Exchange and not on NASDAQ.

I've seen a couple of recent Vlad interviews with LSE and VM on YouTube but I've not been able to find a video or slide deck of anything else since the October 2024 'Bringing Breakthrough Therapies To Patients' slide deck.

Are there any more recent company presentations - for finals and interims as well as company overviews?

So the patients are in the process of being cured. That's great for them and future patients. Thank you for the explanation Haywain.

@ToukanOfDoom

I'm interested but 'cautious'. Any tech investment needs to be based on sound, moated science but there's more to investment than that as you know from getting spiked. Management, funding and buy-in/-out interest are also important. Short of a company coming in and buying Hemogenyx in the next year, with just the first of four Phase 1a cohorts completed and hence a lot more funding required, this company is a long way from a marketted product and profitability. I know how much you love your dividends.

As regards cures, haematologicalcancers and solid tumours are very different beasts. Now that I've elicited a description from Haywain maybe you could describe to me how HG-CT-1 works?

Eggy is allowed to change his mind but CC isn't.

Eggy can change direction but Avacta aren't allowed to.

🤡😂

The consolidation was 400:1 but why the obsession with share price?

What's important is MCap. (Numer of shares) x (Share price) = MCap

You can halve the number of shares and you will instantly double the share price but the MCap stays the same.

And it's pennies, not pennys, but you don't seem to be able to write proper English anyway.

So, to be clear Haywain, you're saying that these three patients have been cured?

Of course the DSMB looks at all available data. So what's in a 'safety' assessment if not all those parameters?

Well, if you'd quoted me in full:

"The efficacy part of the the study is 'preliminary efficacy', meaning does it even work? It may be that at the lowest dose the treatment doesn't show any efficacy, but might at higher doses. That obviously isn't the case here."

...it would have been clear that I was talking about the general case for a Phase 1a (dose escalation) trial.

The DSMB gave 'the nod' because it was safe. The clue is in the name - Data Safety Monitoring Board.

@nps4, you can't KNOW that there is "a patient alive nearly 12months later at the point, another nearly at 9months". All you can KNOW is what the company has put into the public domain, or rather your INTERPRETATION of what the company has put into the public domain.

15 Aug 2025 - https://www.lse.co.uk/rns/HEMO/third-patient-treated-with-hg-ct-1-car-t-therapy-e94pv0bsis7krx9.html "The Company is pleased to report that the first two patients treated with HG-CT-1 remain alive at six months and three months post-treatment, respectively."

17 Sep 2025 - https://www.lse.co.uk/rns/HEMO/third-patient-safety-0wzf8og3t8ibihn.html "... the third patient has been successfully treated ... early indications of clinical efficacy have been observed. Preliminary assessment shows that original AML cells were not detectable in the patient using standard testing methods. ... Safety data from the first three patients treated at the lowest dose of HG-CT-1 will be submitted to an independent Data Safety Monitoring Board (DSMB) for review."

29 Oct 2025 - https://www.lse.co.uk/rns/HEMO/clinical-trial-update-and-grant-of-share-awards-r1xlgv3aa8n6fwf.html "The DSMB's positive recommendation follows the successful completion of initial safety assessments for all three patients treated at the lowest dose, with no dose-limiting toxicities observed. ... The Phase I study of HG-CT-1 is a dose-escalation trial designed to evaluate the safety, tolerability, and preliminary efficacy... The DSMB's clearance to proceed represents a key de-risking milestone in the clinical development of HG-CT-1. It reinforces the favorable safety profile observed to date and signals continued regulatory and operational momentum. For investors, this milestone marks a potential value-inflection point as the Company advances into higher dose cohorts where enhanced efficacy signals are anticipated, paving the way toward broader clinical validation and future pivotal studies."

Apologies if I've missed any other mentions of treated patients and the purpose of this Phase 1 dose escalation trial. Full details of the trial, including incusion/exclusion criteria, and primary and secondary endpoints are given on the ClinicalTrials site: https://clinicaltrials.gov/study/NCT06786533

This is primarily a safety and tolerability study - to prove that the treatment at each dose level won't kill the patients or give them bad side effects (especially grades 3 and 4) or further illnesses. The efficacy part of the the study is 'preliminary efficacy', meaning does it even work? It may be that at the lowest dose the treatment doesn't show any efficacy, but might at higher doses. That obviously isn't the case here. Showing efficacy at this stage doesn't mean cure, prolonged improvement or still alive. The last time the company said in an RNS that patients 1 and 2 were still alive was on 15 August. Patients can die during the trial from disease progression and the dose still be regarded as 'safe' to g

Good data means future trial expenditure and if 'the market' doesn't see how that's going to be funded, then the share price could take a dip. Does 'the market' realise that Avacta has had no difficulty raising money this year and, come the new Tax Year, retail investors are ready to invest more?